Dr. Kazandjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1120 NW 14th St
Rm 828
Miami, FL 33136Phone+1 305-243-5001
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2003 - 2006
Boston University School of MedicineClass of 2003
Certifications & Licensure
VA State Medical License 2004 - 2026
FL State Medical License 2020 - 2025- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Clinical Trials
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry Start of enrollment: 2022 Jul 01
Roles: Contact
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Sep 27
Roles: Contact
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Start of enrollment: 2023 Mar 26
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- From MGUS to multiple myeloma: Unraveling the unknown of precursor states.Gil Hevroni, Mounika Vattigunta, Dickran Kazandjian, David Coffey, Benjamin Diamond
Blood Reviews. 2024-11-01 - 1 citationsGenomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.Dickran Kazandjian, Benjamin Diamond, Marios Papadimitriou, Elizabeth Hill, Romanos Sklavenitis-Pistofidis
Clinical Cancer Research. 2024-10-01 - 7 citationsEVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.Ola Landgren, Thomas J Prior, Tara Masterson, Christoph Heuck, Orlando F Bueno
Blood. 2024-07-25
Abstracts/Posters
- Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to DisagreeDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple MyelomaDickran Kazandjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition - Tip SheetNovember 13th, 2024- Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024
- Sylvester Cancer Tip Sheet: Researchers Present Posters at the 66th ASH Annual Meeting & ExpositionNovember 13th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
